Description

Cyclosporine: Co-administration of cyclosporine with Pitavastatin is contraindicated. Erythromycin: Erythromycin significantly increased Pitavastatin exposure. In patients taking erythromycin, a dose of Pitavastatin 1 mg once daily should not be exceeded. Rifampin: Rifampin significantly increased Pitavastatin exposure. In patients taking rifampin, a dose of Pitavastatin 2 mg once daily should not be exceeded. Fibrates: Pitavastatin should be administered with caution when used concomitantly with gemfibrozil or other fibrates. Warfarin: Pitavastatin had no significant pharmacokinetic interaction with warfarin.

Rhabdomyolysis, myopathy and Liver enzyme abnormalities.

Pregnancy Category X. Pitavastatin is contraindicated in women who are or may become pregnant. It is not known whether Pitavastatin is excreted in human milk, however, it has been shown that a small amount of another drug in this class passes into human milk.

Pitavastatin should be prescribed with caution in patients with predisposing factors for myopathy. These factors include advanced age (>65 years), renal impairment, and inadequately treated hypothyroidism. Increase in serum transaminases have been reported with HMG-CoA reductase inhibitors, including Pitavastatin. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy.

There is no known specific treatment in the event of overdose of Pitavastatin. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Hemodialysis is unlikely to be of benefit due to high protein binding ratio of Pitavastatin.

Other Anti-anginal & Anti-ischaemic drugs, Statins

Store in a cool and dry place, protect from light & moisture . Keep out of the reach of children.